SG11202011015QA - Fusosome compositions and uses thereof - Google Patents

Fusosome compositions and uses thereof

Info

Publication number
SG11202011015QA
SG11202011015QA SG11202011015QA SG11202011015QA SG11202011015QA SG 11202011015Q A SG11202011015Q A SG 11202011015QA SG 11202011015Q A SG11202011015Q A SG 11202011015QA SG 11202011015Q A SG11202011015Q A SG 11202011015QA SG 11202011015Q A SG11202011015Q A SG 11202011015QA
Authority
SG
Singapore
Prior art keywords
fusosome compositions
fusosome
compositions
Prior art date
Application number
SG11202011015QA
Inventor
Maltzahn Geoffrey Von
Jacob Rubens
Michael Mee
John Milwid
Neal Gordon
Jagesh Shah
Kyle Trudeau
Brigham Hartley
Peter Jones
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of SG11202011015QA publication Critical patent/SG11202011015QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11202011015QA 2018-05-15 2019-05-15 Fusosome compositions and uses thereof SG11202011015QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671838P 2018-05-15 2018-05-15
US201862695529P 2018-07-09 2018-07-09
PCT/US2019/032488 WO2019222403A2 (en) 2018-05-15 2019-05-15 Fusosome compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11202011015QA true SG11202011015QA (en) 2020-12-30

Family

ID=67303499

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011015QA SG11202011015QA (en) 2018-05-15 2019-05-15 Fusosome compositions and uses thereof

Country Status (11)

Country Link
US (1) US20210228627A1 (en)
EP (1) EP3793570A2 (en)
JP (1) JP2021523724A (en)
KR (1) KR20210021473A (en)
CN (1) CN112367973A (en)
AU (1) AU2019269593A1 (en)
BR (1) BR112020023015A2 (en)
CA (1) CA3099497A1 (en)
MX (1) MX2020012295A (en)
SG (1) SG11202011015QA (en)
WO (1) WO2019222403A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
KR20200034668A (en) 2017-05-08 2020-03-31 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Composition for promoting membrane fusion and use thereof
AU2019378883A1 (en) * 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
CA3143327A1 (en) * 2019-06-13 2020-12-17 J. Keith Joung Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP4025698A1 (en) 2019-09-03 2022-07-13 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
US20220340914A1 (en) * 2019-12-10 2022-10-27 Repligen Corporation Methods of preparing viral vectors
IL296621A (en) * 2020-03-31 2022-11-01 Sana Biotechnology Inc Targeted lipid particles and compositions and uses thereof
WO2022055894A1 (en) * 2020-09-08 2022-03-17 The Regents Of The University Of California Sars-cov-2 spike glycoprotein for virus generation and pseudotyping
AU2022206324A1 (en) * 2021-01-11 2023-07-20 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
EP4298228A1 (en) * 2021-02-23 2024-01-03 Mayo Foundation for Medical Education and Research Engineering hemagglutinin and fusion polypeptides of canine distemper virus
IL307544A (en) 2021-04-08 2023-12-01 Sana Biotechnology Inc Cd8-specific antibody constructs and compositions thereof
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
TW202321457A (en) 2021-08-04 2023-06-01 美商薩那生物科技公司 Use of cd4-targeted viral vectors
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2023092078A1 (en) * 2021-11-18 2023-05-25 The Broad Institute, Inc. Retargeted retroviral vectors and compositions or methods of use thereof
TW202342757A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae attachment glycoproteins
TW202342498A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae fusion glycoproteins
WO2023133595A2 (en) * 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
AU2589095A (en) 1994-05-16 1995-12-05 Washington University Cell membrane fusion composition and method
WO1997004748A2 (en) * 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CZ137399A3 (en) 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retroviral production system for producing replication defective vector particles
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
AU9399498A (en) 1997-09-18 1999-04-05 Trustees Of The University Of Pennsylvania, The Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
WO2000017374A1 (en) * 1998-09-23 2000-03-30 Austrian Nordic Biotherapeutics Ag Retroviral particles protected against complement mediated destruction
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2002002765A2 (en) * 2000-07-05 2002-01-10 Transgene S.A. Chimeric promoters for controlling expression in smooth muscle cells
CA2325088A1 (en) * 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
JP2005521398A (en) 2002-03-27 2005-07-21 ベイラー　カレッジ　オブ　メディスン A powerful oncolytic herpes simplex virus for cancer treatment
ES2627445T3 (en) 2002-05-01 2017-07-28 Miltenyi Biotec Technology, Inc. Lentivirus vector particles resistant to complement inactivation
ATE494362T1 (en) 2002-05-14 2011-01-15 Merck Sharp & Dohme METHOD FOR PURIFYING ADENOVIRUS
CN100488491C (en) 2002-11-21 2009-05-20 派维翁生物技术有限公司 High-efficiency fused vesicles, methods of producing them, and pharmaceutical compositions containing same
US7842673B2 (en) 2003-12-17 2010-11-30 The Trustees Of Columbia University In The City Of New York Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
JP2008518630A (en) 2004-11-08 2008-06-05 イェール ユニバーシティ Riboswitch, structure-based compound design by riboswitch, and method of using riboswitch and composition with riboswitch
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
WO2008071959A1 (en) * 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
US9050269B2 (en) 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
US8697439B2 (en) 2009-11-13 2014-04-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Direct protein delivery with engineered microvesicles
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
KR20150029756A (en) * 2011-06-10 2015-03-18 블루버드 바이오, 인코포레이티드. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
KR102541164B1 (en) * 2014-01-21 2023-06-08 안자리움 바이오사이언시스 아게 Hybridosomes, compositions comprising the same, processes for their production and uses thereof
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
US20180163178A1 (en) * 2015-05-29 2018-06-14 Robert J. Schneider Auf1 encoding compositions for muscle cell uptake, satellite cell populations, and satellite cell mediated muscle generation
US20170112773A1 (en) 2015-10-23 2017-04-27 Board Of Regents, The University Of Texas System Plasma membrane vesicles comprising functional transmembrane proteins
WO2017151717A1 (en) * 2016-03-01 2017-09-08 French Brent A Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
EP3235908A1 (en) * 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
KR20190043520A (en) * 2016-06-09 2019-04-26 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 Herpes virus with modified glycoprotein H for intracellular propagation
AU2017292936C1 (en) * 2016-07-08 2024-05-02 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
JP2019521717A (en) * 2016-07-26 2019-08-08 センティ バイオサイエンシズ インコーポレイテッド Gene eraser
AU2017301881A1 (en) 2016-07-29 2019-02-07 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
MX2020008152A (en) * 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii.

Also Published As

Publication number Publication date
AU2019269593A1 (en) 2020-11-26
CN112367973A (en) 2021-02-12
EP3793570A2 (en) 2021-03-24
MX2020012295A (en) 2021-03-31
CA3099497A1 (en) 2019-11-21
WO2019222403A3 (en) 2019-12-12
KR20210021473A (en) 2021-02-26
BR112020023015A2 (en) 2021-02-17
JP2021523724A (en) 2021-09-09
WO2019222403A2 (en) 2019-11-21
US20210228627A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
IL279897A (en) Fusosome compositions and uses thereof
SG11202011015QA (en) Fusosome compositions and uses thereof
IL271275A (en) Compositions comprising curons and uses thereof
IL279755A (en) Senolytic compositions and uses thereof
GB201815402D0 (en) Compositions and methods and uses relating thereto
GB2578519B (en) Compositions and methods and uses relating thereto
IL277663A (en) Erenumab compositions and uses thereof
GB201807576D0 (en) Compositions and uses thereof
GB201712592D0 (en) Novel compositions and uses thereof
GB201821138D0 (en) Compositions and uses thereof
GB201812334D0 (en) Compositions and uses thereof
GB201821144D0 (en) Compositions and uses thereof
GB201819493D0 (en) Compositions and uses thereof
GB201818495D0 (en) Compositions and uses thereof
GB201818375D0 (en) Compositions and uses thereof
GB201808907D0 (en) Compositions and uses thereof
GB201808858D0 (en) Compositions and uses thereof
GB201808321D0 (en) Compositions and uses thereof
GB201808298D0 (en) Compositions and uses thereof
GB201805322D0 (en) Compositions and uses thereof
GB201805093D0 (en) Compositions and uses thereof
GB201805097D0 (en) Compositions and uses thereof
GB201805098D0 (en) Compositions and uses thereof
GB201804407D0 (en) Compositions and uses thereof
GB201907351D0 (en) Compositions and uses thereof